High Blood Cholesterol Clinical Trial
— CEPHEUSOfficial title:
CEPHEUS Centralized Pan-Levant Survey on the Undertreatment of Hypercholesterolemia NIS-LT-CRE-2010/01 Version 1.0
| Verified date | June 2012 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Jordan: Ethical CommitteeLebanon: Ministry of Public Health |
| Study type | Observational |
This was a multicenter survey of patients who were on lipid -lowering pharmacological
treatment in 2 Levant countries namely Jordan and Lebanon. The purpose is to study the
effects of cholesterol lowering drugs on the blood cholesterol levels of patients in Jordan
and Lebanon.
Data collected from each patient took place at a single visit. Each participating doctor
filled the investigator questionnaire on his/her experience and perception of the management
of the hypercholesterolemia of his/her patients. Each doctor was asked to indicate his/her
general attitude on the diagnosis of hypercholesterolemia, the existing guidelines and goals
and the various treatment options for high cholesterol in blood.
Before being assessed by the investigator, patients recorded, on the patient questionnaire,
their awareness of high blood cholesterol , their current lipid-lowering treatment schedule,
their understanding of their condition and compliance in taking the medications on time.
The investigators completed a Patient Record Form (PRF) with the patient's basic
information, cardiovascular risk factors and the cardiovascular medical history, current
lipid lowering drug treatment and the reason for the current therapy.
A blood sample under fasting condition was drawn from each subject. A central laboratory in
Jordan received all samples. Every sample was analyzed for its cholesterol blood level,
fasting sugar level and hemoglobin A1C levels.
| Status | Completed |
| Enrollment | 1000 |
| Est. completion date | December 2010 |
| Est. primary completion date | December 2010 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Adult patients with high cholesterol blood levels willing to participate in the study - Patients must be on cholesterol lowering medications for three months with no dose change for six weeks Exclusion Criteria: - Patients not on cholesterol lowering medications or on medications for less than three months - Any medication dose change in six weeks prior to their visit |
Observational Model: Case-Only, Time Perspective: Cross-Sectional
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number and percentage of subjects achieving the LDL-C goals, according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines, in Jordan and Lebanon | 5 months- One visit only, no follow up visits | No | |
| Secondary | Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III / 2004 updated NCEP ATP III guidelines, for several subject subsets | 5 months- One visit only, no follow up visits | No | |
| Secondary | Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and for several subject subsets | 5 months- One visit only, no follow up visits | No | |
| Secondary | Number and percentage of subjects achieving the non HDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III / national guidelines (<130 mg/dL), in the following sub-population: patients with fasting triglycerides >200 mg/dL. | 5 months- One visit only, no follow up visits | No | |
| Secondary | Achievement of LDL-C goals, according to the Third Joint European Task Force TJETF / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables. Assessed using Multivariate logistic regression mode | 5 months- One visit only, no follow up visits | No | |
| Secondary | Physician characteristics associated with the allocation of treatment regimen. | 5 months- One visit only, no follow up visits | No |